FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine. A method of reducing Aβ, Aβ deposition, neurotoxicity and microglyosis in an animal or a human suffering a cerebral amyloidogenic disease, involving administering a therapeutically effective amount of enantiomer-rich (-)-nilvadipine into the animal or human. The further methods represent methods of reducing a risk of Aβ, Aβ deposition, neurotoxicity and microglyosis in the animal or human suffering the traumatic cerebral affection by administering (-)-nilvadipine following the traumatic cerebral affection with the treatment continued for a specified period of time. A pharmaceutical composition for reducing Aβ, Aβ deposition, neurotoxicity and microglyosis in the animal or human suffering a cerebral amyloidogenic disease containing the therapeutically effective amount of optically active nilvadipine and a pharmaceutically acceptable carrier with the pharmaceutical composition containing a residue of (-)-nilvadipine as compared to (+)-nilvadipine, particularly at least 90% as compared to (+)-nilvadipine.
EFFECT: invention provides higher clinical effectiveness.
22 cl, 10 ex, 18 dwg
